{
    "nct_id": "NCT03361865",
    "official_title": "A Phase 3 Randomized, Double-Blind Trial of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) or Placebo in Participants With Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)",
    "inclusion_criteria": "* Histologically or cytologically-confirmed diagnosis of advanced/unresectable (inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or urethra.\n* Measurable disease based on RECIST v1.1.\n* Be considered ineligible to receive cisplatin-based combination therapy, based on protocol-defined criteria.\n* Have provided tissue for PD-L1 analysis from an archival tissue sample or newly obtained core or excisional biopsy of a tumor lesion not previously irradiated.\n* Have received no prior systemic chemotherapy for advanced/unresectable (inoperable) or metastatic urothelial cancer.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2 within 14 days prior to randomization.\n* Adequate organ function per protocol-defined criteria.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Disease that is suitable for local therapy administered with curative intent.\n* Known additional malignancy that is progressing or has required active treatment within the past 3 years.\n* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, ie, without evidence of progression for at least 4 weeks by repeat imaging, clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.\n* Known history of or is positive for active hepatitis B (hepatitis B surface antigen [HBsAg] reactive) or has active hepatitis C (HCV RNA). Note: Testing must be performed to determine eligibility.\n* History of a gastrointestinal condition that in the opinion of the Investigator may affect oral drug absorption.\n* History or presence of an abnormal electrocardiogram (ECG) that, in the investigator's opinion, is clinically meaningful.\n* Use of protocol-defined prior/concomitant therapy.",
    "miscellaneous_criteria": ""
}